| Publication | Date of Publication | Type |
|---|
| Commentary on ``Principal stratification -- a goal or a tool? by Judea Pearl | 2024-11-27 | Paper |
| A hybrid approach for the stratified mark-specific proportional hazards model with missing covariates and missing marks, with application to vaccine efficacy trials | 2024-11-21 | Paper |
| Inferences on relative failure rates in stratified mark-specific proportional hazards models with missing marks, with application to human immunodeficiency virus vaccine efficacy trials | 2024-11-14 | Paper |
| Simultaneous inference of treatment effect modification by intermediate response endpoint principal strata with application to vaccine trials | 2024-11-12 | Paper |
| A varying-coefficient partially linear transformation model for length-biased data with an application to HIV vaccine studies | 2024-11-12 | Paper |
| Semiparametric regression analysis of partly interval-censored failure time data with application to an AIDS clinical trial | 2024-10-29 | Paper |
| Assessing pharmacokinetic marker correlates of outcome, with application to antibody prevention efficacy trials | 2024-10-29 | Paper |
| A semiparametric Cox-Aalen transformation model with censored data | 2024-08-19 | Paper |
| Inference for Treatment-Specific Survival Curves Using Machine Learning | 2024-07-05 | Paper |
| Estimation of conditional cumulative incidence functions under generalized semiparametric regression models with missing covariates, with application to analysis of biomarker correlates in vaccine trials | 2023-11-02 | Paper |
| Efficient nonparametric inference on the effects of stochastic interventions under two‐phase sampling, with applications to vaccine efficacy trials | 2023-10-30 | Paper |
| Nonparametric Estimation of the Causal Effect of a Stochastic Threshold-Based Intervention | 2023-10-30 | Paper |
| Semiparametric Additive Time-Varying Coefficients Model for Longitudinal Data with Censored Time Origin | 2023-10-30 | Paper |
| A General Framework for Inference on Algorithm-Agnostic Variable Importance | 2023-10-18 | Paper |
| Nonparametric variable importance assessment using machine learning techniques | 2023-10-09 | Paper |
| Rejoinder to “Nonparametric variable importance assessment using machine learning techniques” | 2023-10-09 | Paper |
| Sensitivity analysis for evaluating principal surrogate endpoints relaxing the equal early clinical risk assumption | 2022-09-05 | Paper |
| Semiparametric Estimation of Treatment Effects Given Base-Line Covariates on an Outcome Measured After a Post-Randomization Event Occurs | 2022-07-11 | Paper |
| Causal Isotonic Regression | 2022-07-08 | Paper |
| A Multiple Imputation Approach for the Evaluation of Surrogate Markers in the Principal Stratification Causal Inference Framework | 2021-04-20 | Paper |
| General regression model for the subdistribution of a competing risk under left-truncation and right-censoring | 2021-01-21 | Paper |
| Analysis of the time-varying Cox model for the cause-specific hazard functions with missing causes | 2021-01-18 | Paper |
| Semiparametric estimation of the average causal effect of treatment on an outcome measured after a postrandomization event, with missing outcome data | 2020-08-04 | Paper |
| https://portal.mardi4nfdi.de/entity/Q3295868 | 2020-07-13 | Paper |
| Analysis of generalized semiparametric mixed varying‐coefficients models for longitudinal data | 2020-04-28 | Paper |
| New approaches for censored longitudinal data in joint modelling of longitudinal and survival data, with application to HIV vaccine studies | 2019-10-01 | Paper |
| Nonparametric inference for immune response thresholds of risk in vaccine studies | 2019-08-15 | Paper |
| Predicting overall vaccine efficacy in a new setting by re-calibrating baseline covariate and intermediate response endpoint effect modifiers of type-specific vaccine efficacy | 2019-07-11 | Paper |
| Doubly robust nonparametric inference on the average treatment effect | 2019-06-24 | Paper |
| Smoothed Rank Regression for the Accelerated Failure Time Competing Risks Model with Missing Cause of Failure | 2019-02-28 | Paper |
| Analysis of generalized semiparametric regression models for cumulative incidence functions with missing covariates | 2018-08-17 | Paper |
| Goodness-of-fit test of the stratified mark-specific proportional hazards model with continuous mark | 2018-08-15 | Paper |
| Hypothesis tests for stratified mark‐specific proportional hazards models with missing covariates, with application to HIV vaccine efficacy trials | 2018-05-31 | Paper |
| Mark-specific hazard ratio model with missing multivariate marks | 2017-08-17 | Paper |
| Model‐robust inference for continuous threshold regression models | 2017-07-21 | Paper |
| Generalized semiparametric varying‐coefficient model for longitudinal data with applications to adaptive treatment randomizations | 2017-07-21 | Paper |
| Analysis of two-phase sampling data with semiparametric additive hazards models | 2017-07-17 | Paper |
| Joint modeling of longitudinal and survival data with the Cox model and two-phase sampling | 2017-05-23 | Paper |
| Nonparametric bounds and sensitivity analysis of treatment effects | 2016-03-04 | Paper |
| Mark-specific hazard ratio model with missing multivariate marks | 2015-10-28 | Paper |
| Sensitivity Analysis of Per-Protocol Time-to-Event Treatment Efficacy in Randomized Clinical Trials | 2013-11-11 | Paper |
| Mark-specific hazard ratio model with multivariate continuous marks: an application to vaccine efficacy | 2013-09-05 | Paper |
| Design and estimation for evaluating principal surrogate markers in vaccine trials | 2013-09-05 | Paper |
| SIMULTANEOUS INFERENCES OF HIV VACCINE EFFECTS ON VIRAL LOAD, CD4 CELL COUNTS, AND ANTIRETROVIRAL THERAPY INITIATION IN PHASE 3 TRIALS | 2013-07-31 | Paper |
| Partially Hidden Markov Model for Time-Varying Principal Stratification in HIV Prevention Trials | 2013-04-22 | Paper |
| Mark-specific hazard ratio model with multivariate continuous marks: an application to vaccine efficacy | 2013-02-19 | Paper |
| Assessing Treatment‐Selection Markers using a Potential Outcomes Framework | 2012-11-19 | Paper |
| Estimation of stratified mark-specific proportional hazards models with missing marks | 2012-09-01 | Paper |
| Comparing biomarkers as principal surrogate endpoints | 2012-06-20 | Paper |
| Quantile regression for competing risks data with missing cause of failure | 2012-05-14 | Paper |
| Sensitivity Analyses Comparing Time-to-Event Outcomes Only Existing in a Subset Selected Postrandomization and Relaxing Monotonicity | 2011-11-21 | Paper |
| Sensitivity Analysis for the Assessment of Causal Vaccine Effects on Viral Load in HIV Vaccine Trials | 2011-03-01 | Paper |
| Simultaneous Inferences on the Contrast of Two Hazard Functions with Censored Observations | 2011-03-01 | Paper |
| Flexible Weighted Log-Rank Tests Optimal for Detecting Early and/or Late Survival Differences | 2011-03-01 | Paper |
| Omnibus Tests for Comparison of Competing Risks with Adjustment for Covariate Effects | 2011-03-01 | Paper |
| Statistical Identifiability and the Surrogate Endpoint Problem, with Application to Vaccine Trials | 2011-02-17 | Paper |
| Assessing Vaccine Effects in Repeated Low‐Dose Challenge Experiments | 2010-01-21 | Paper |
| Proportional hazards models with continuous marks | 2009-02-25 | Paper |
| Weighted Likelihood Method for Grouped Survival Data in Case–Cohort Studies with Application to HIV Vaccine Trials | 2008-12-22 | Paper |
| Evaluating Candidate Principal Surrogate Endpoints | 2008-12-22 | Paper |
| Testing and Estimation of Time‐Varying Cause‐Specific Hazard Ratios with Covariate Adjustment | 2008-12-22 | Paper |
| The 2-sample problem for failure rates depending on a continuous mark: an application to vaccine efficacy | 2008-09-25 | Paper |
| Assessing surrogate endpoints in vaccine trials with case-cohort sampling and the Cox model | 2008-04-30 | Paper |
| Nonparametric Estimation of the Joint Distribution of a Survival Time Subject to Interval Censoring and a Continuous Mark Variable | 2008-04-29 | Paper |
| Genome Scanning Tests for Comparing Amino Acid Sequences Between Groups | 2008-03-20 | Paper |
| Endpoints in vaccine trials | 2007-11-05 | Paper |
| Some statistical issues in the design of HIV-1 vaccine and treatment trials | 2007-11-01 | Paper |
| Sensitivity Analyses Comparing Time-to-Event Outcomes Existing Only in a Subset Selected Postrandomization | 2007-09-18 | Paper |
| A Modified False Discovery Rate Multiple-Comparisons Procedure for Discrete Data, Applied to Human Immunodeficiency Virus Genetics | 2007-09-07 | Paper |
| Sensitivity Analyses Comparing Outcomes Only Existing in a Subset Selected Post‐Randomization, Conditional on Covariates, with Application to HIV Vaccine Trials | 2006-10-12 | Paper |
| Two‐Sample Tests for Comparing Intra‐Individual Genetic Sequence Diversity between Populations | 2006-01-03 | Paper |
| Failure time analysis of HIV vaccine effects on viral load and antiretroviral therapy initiation | 2005-09-29 | Paper |
| Statistical Methods for Assessing Differential Vaccine Protection Against Human Immunodeficiency Virus Types | 2005-04-11 | Paper |
| Tests for comparing mark-specific hazards and cumulative incidence functions | 2005-01-17 | Paper |
| Goodness-of-fit tests for semiparametric biased sampling models | 2003-12-14 | Paper |
| Large sample theory of maximum likelihood estimates in semiparametric biased sampling models. | 2002-11-14 | Paper |
| Applications of semiparametric biased sampling models to AIDS vaccine and treatment trials | 2002-05-13 | Paper |
| Semiparametric efficient estimation in the generalized odds-rate class of regression models for right-censored time-to-event data | 2000-08-10 | Paper |
| Maximum likelihood estimation in semiparametric selection bias models with application to AIDS vaccine trials | 1999-07-05 | Paper |
